A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
about
DNA damage response and prostate cancer: defects, regulation and therapeutic implicationsActivation of Akt signaling in prostate induces a TGFβ-mediated restraint on cancer progression and metastasis.Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Prostate cancer induced by loss of Apc is restrained by TGFβ signalingMouse models of prostate cancer: picking the best model for the question.Antioxidant treatment promotes prostate epithelial proliferation in Nkx3.1 mutant mice.MCT-1 expression and PTEN deficiency synergistically promote neoplastic multinucleation through the Src/p190B signaling activation.Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivityGene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.Profiling prostate cancer.Molecular classification of prostate cancer using curated expression signaturesRegulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee.Recent progress in mouse models for tumor suppressor genes and its implications in human cancer.Molecular pathogenesis and progression of prostate cancerCombined MYC Activation and Pten Loss Are Sufficient to Create Genomic Instability and Lethal Metastatic Prostate CancerTherapeutic Approaches Targeting MYC-Driven Prostate CancerModeling prostate cancer in mice: something old, something new, something premalignant, something metastatic.Current mouse and cell models in prostate cancer research.Drug discovery in prostate cancer mouse models.Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination.MYC, Metabolic Synthetic Lethality, and Cancer.NVP-LDE-225 (Erismodegib) inhibits epithelial-mesenchymal transition and human prostate cancer stem cell growth in NOD/SCID IL2Rγ null mice by regulating Bmi-1 and microRNA-128.Modeling African American prostate adenocarcinoma by inducing defined genetic alterations in organoidsRapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.The genomic landscape of prostate cancer.Epigenetic Regulation in Prostate Cancer Progression.The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.
P2860
Q26829155-0F6789BD-B75D-4A9A-B8C4-6092F61B4DC6Q30408632-1463863B-03AF-4907-8D14-AC343B7B1CCBQ30409623-FDC06D38-A523-4DF5-86A1-BEC01A24A889Q30414232-CB0EDD82-2C43-4915-BAF5-170791BC499EQ33940867-F8A6E3E8-00C3-4371-9182-3E2F2FCB4BFFQ34450412-FD8B03AE-9A4B-41C7-83C4-592B517CB902Q34876968-7125A913-5456-4E15-8A7E-1DF8AAC01194Q35176093-3B923051-6B96-4FF6-BACA-F06215CB3C0DQ35223291-DE16DF97-59FD-4602-961D-B6EFBDC8C9A6Q35641430-4602FB2B-4DF6-41ED-A170-7FC45FDA67E3Q35641563-AACE3038-0025-4342-B45A-6E56B13F73B2Q36590632-8C122A85-0B61-473B-A323-325ABDD51826Q36815316-65E6366D-C7CB-4B64-9F59-D9EE39E836D2Q36929407-C48C4846-5FFD-4A3E-900F-F7DB3F1C5FB4Q37055715-FFF7771C-3190-4ABF-816C-ACBA07E8C157Q37221588-7A255684-7070-496F-AE75-8CBAA3C3EF94Q37676253-D3B0FE2B-3558-410A-8BC1-88723CC1A000Q38056848-513B1026-CAF9-4CDD-A7BF-D8822BBE5A33Q38098499-C8D12ED3-CDC4-4E52-85E5-1205DB690213Q38509211-3D43A3DB-E98F-4A8D-B3C1-B2FBF813EDBBQ38727361-4A95289F-89D1-4EC6-BF53-0CB0512679C8Q38936255-5A58304F-A88A-4E3D-8AF9-4C692F86B91BQ40289695-07AE40E4-B469-48F1-A84A-D8476BADFB96Q41612728-6D4F262D-6F37-4794-8E0D-91667BBB86E8Q41960947-5A2F666E-7D34-441C-95F0-BD0D45996663Q42174920-18533EC0-DC0E-4372-AEF5-4233EE31F6E1Q54974720-8D2B72AA-77C1-47DE-8A24-F88F45173D7BQ55425609-EAD87920-65C0-4E85-B4E9-1443C5E042CD
P2860
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@ast
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@en
type
label
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@ast
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@en
prefLabel
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@ast
A mouse model of heterogeneous ...... cer with loss of Pten and p53.
@en
P2093
P2860
P356
P1433
P1476
A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53
@en
P2093
I Doubinskaia
I-E A Eltoum
S A Abdulkadir
P2860
P2888
P304
P356
10.1038/ONC.2011.236
P407
P577
2011-06-20T00:00:00Z
P5875
P6179
1042097438